Basilea Pharmaceutica AG (BPMUF.PK)

BPMUF.PK on OTC Markets Group

100.60USD
26 Aug 2015
Change (% chg)

$3.55 (+3.53%)
Prev Close
$100.60
Open
$104.15
Day's High
$104.15
Day's Low
$104.15
Volume
50
Avg. Vol
228
52-wk High
$142.33
52-wk Low
$85.40

BPMUF.PK

Chart for BPMUF.PK

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.58
Market Cap(Mil.): CHF1,032.29
Shares Outstanding(Mil.): 10.79
Dividend: --
Yield (%): --

Financials

  BPMUF.PK Industry Sector
P/E (TTM): -- 60.09 34.00
EPS (TTM): -5.32 -- --
ROI: -25.76 0.02 14.57
ROE: -89.93 -0.16 15.46
Search Stocks

BRIEF-Basilea Pharmaceutica H1 net loss widens to CHF 30.1 mln

* Announced today its financial results for first half of financial year 2015 with a solid half-year cash position of 218.4 million Swiss francs ($223.91 million)

14 Aug 2015

BRIEF-Basilea Pharmaceutica: ceftobiprole receives QIDP designation from FDA for treatment of lung and skin infections

* Basilea Pharmaceutica AG reports that ceftobiprole received Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of lung and skin infections Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Aug 2015

BRIEF-Basilea Pharmaceutica: topline results of isavuconazole phase 3 study in candidemia

* Reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections

30 Jul 2015

BRIEF-Basilea Pharmaceutica starts clinical phase 1/2a study with oral formulation of its BAL101553

* Initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

25 Jun 2015

BRIEF-Basilea Pharmaceutica reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor

* Said on Monday it reported start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor

05 May 2015

BRIEF-Basilea Pharmaceutica in-licenses targeted cancer therapy

* Entered into license agreement for novel panRAF kinase inhibitors with consortium of organizations including Institute Of Cancer Research, London, Cancer Research Technology, Wellcome Trust and University Of Manchester Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Apr 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$49.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks